Catalyst ligands

29841-69-8, (1S,2S)-(-)-1,2-Diphenylethylenediamine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: (1R, 2R)-N-p-styrenesulfonyl-1,2-diphenylethylenediamine was synthesized as follows: 1g of (1R, 2R)-1,2-diphenylethylenediamine (4.71mmol) was dissolved in 20mL of CH2Cl2 in the presence of excessive of triethylamine and cooled to 0C, followed by the slow addition of 5mL of CH2Cl2 solution containing 1g of p-styrenesulfonyl chloride (4.78mmol), and stirred at room temperature overnight. The solution was washed with 5% NaOH aqueous solution, dried with MgSO4, and evaporated under vacuum to remove the solvent. The obtained solid was dissolved in diethyl ether, followed by the addition of 1mL of concentrated HCl (37wt%). The formed white precipitated was filtrated, treated with 5% NaOH aqueous, and then extracted with CH2Cl2 for 3 times. The combined organic phase was washed thoroughly with brine and dried over with MgSO4. The solvent was removed under vacuum and 1.28g of light yellow solid (72% yield) was obtained, which was denoted as V-TsDPEN [11]. 1H NMR (400MHz, DMSO-d6, 298K, TMS): delta6.64-7.38 (m, 14H), 6.64-6.67 (m, 1H), 5.87 (d, 1H, J=16.8Hz), 5.35 (d, 1H, J=11.2Hz), 4.33 (d, 1H, J=7.2Hz), 3.95 (d, 1H, J=6.6Hz) ppm., 29841-69-8

As the paragraph descriping shows that 29841-69-8 is playing an increasingly important role.

Reference£º
Article; Sun, Qi; Jin, Yinying; Zhu, Longfeng; Wang, Liang; Meng, Xiangju; Xiao, Feng-Shou; Nano Today; vol. 8; 4; (2013); p. 342 – 350;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

29176-55-4, 2,9-Dichloro-1,10-phenanthroline is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Preparation of E-l-(6-methyl-pyridin-2-yl)-ethanone-O-r3-(9-chloro-rif101phenanthrolin- 2-yl)-prop-2-ynyl1-oxime2,9-Dichloro-[l,10]phenanthroline (0.46 g) and E-l-(6-methyl-pyridin-2-yl)-ethanone-0- prop-2-ynyl-oxime (382 mg) were dissolved in THF (5 ml_). Diisopropylamine (1.88 g), dichlorobis (triphenylphospine)palladium(II) (57 mg) and copper(I) iodide (58 mg) were added. After stirring for 3h at 55C the reaction mixture was poured into water, extracted with ethyl acetate and washed with brine. The organic phase was dried over sodium sulfate, concentrated and purified by chromatography over silica to give l-(6-Methyl-pyridin-2-yl ethanone-O-[3-(9-chloro-[l,10]phenanthrolin-2-yl)-prop-2-ynyl]-oxime as a brown solid., 29176-55-4

The synthetic route of 29176-55-4 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; SYNGENTA PARTICIPATIONS AG; TRAH, Stephan; ZAMBACH, Werner; STIERLI, Daniel; NEBEL, Kurt; BORTOLATO, Andrea; WO2012/62844; (2012); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.137076-54-1,2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid,as a common compound, the synthetic route is as follows.

(2)1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid tri-tert-butyl (8.3 mg)In DMF (0.1 mL) and DIEA (10 [mu] L)A solution of HBTU (5.5 mg) in DMF (100 muL) was added, (N1) (4.6 mg) in DMF (200 muL) and DIEA (20 muL)And the mixture was stirred at room temperature for 1.5 hours. Water (100 muL) was added,Purification by preparative HPLC gave (N 2) (3.5 mg).

137076-54-1, The synthetic route of 137076-54-1 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; FUJIFILM Corporation; Fujifilm RI Pharma Co., Ltd.; Hirofumi, Fukunaga; Do En, Hiroyuki; Hino, Akihiro; Oshikiri, Shinobu; Chou, Rumpf; (131 pag.)JP2016/183151; (2016); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.137076-54-1,2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid,as a common compound, the synthetic route is as follows.

The solids thus obtained were redissolved in DMF andsuccessively treated with HOBt (45.9 mg, 0.300 mmol), 2-(1,4,7,10-tetraaza-4,7,10-tris{[(tert-butyl)oxycarbonyl]methyl}-cyclododecyl)acetic acid (172 mg, 0.300 mmol), i-Pr2NEt(105 muL, 0.600 mmol) and HBTU (1 14 mg, 0.300 mmol) at 22 C.After 0.25 h, complete acylation was observed; only trace amounts ofregioisomeric and dimericproducts formed. The resulting solution was partitioned between EtOAcand H2O (50 mL each) with transfer to a separatory funnel. Thelayers separated and the aqueous layer washed with EtOAc (2 x 50 mL). The EtOAcsolution was further washed with 0.1 M NaOH (3 x 50 mL) and saturated aqueousNaCl (3 x 50 mL each), then dried over MgSO4, filtered andconcentrated in vacuo to a pale yellow oil that was used without furtherpurification in the subsequent deprotection step., 137076-54-1

137076-54-1 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid 11606627, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Lantheus Medical Imaging, Inc.; Sesady, Richard Al; Harris, Thomas?D; Robinson, Simon P; Ruby, Richard J; Jijimon, Edward H; Yallamanchilli, Padmaja; Cosebio, David S; (97 pag.)KR101595324; (2016); B1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4568-71-2,3-Benzyl-5-(2-hydroxyethyl)-4-methylthiazol-3-ium chloride,as a common compound, the synthetic route is as follows.

1-(3-Methoxy-4-propoxy-5-iodophenyl)-4-(3,4,5-trimethoxyphenyl)-1,4-butanedione (compound 126, FIG. 5) 3,4,5-Trimethoxyphenylvinylketone (11.6 g, 0.052 mol), 3-methoxy-4-propoxy-5-iodobenzaldehyde (13.8 g, 0.043 mol), and 3-benzyl-5-(2-hydroxyethyl)-4-methylthiazolium chloride (4.6 g. 0.017 mol) were stirred in trimethylamine (35 mL) at 60¡ã C. for 16 hours. The solution was then acidified, poured into chloroform (500 mL) and washed with 10percent HCl, water and saturated aqueous sodium chloride. The organic layer was dried over magnesium sulfate, concentrated under reduced pressure, and the product isolated from petroleum ether-ethyl acetate to provide pale yellow microcrystals (27 g, 92percent), m.p. 119¡ã-121¡ã C. 1 H NMR (CDCl3) 1.07 (t, 3 H), 1.86 (m, 2 H), 3.40 (dd, 4H), 3.88 (s, 3H), 3.92 (s, 9H), 4.04 (t, 2 H), 7.29 (d, 1 H), 8.07 (d, 1 H).

4568-71-2, As the paragraph descriping shows that 4568-71-2 is playing an increasingly important role.

Reference£º
Patent; CytoMed, Inc.; US5358938; (1994); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4411-80-7,6,6′-Dimethyl-2,2′-bipyridine,as a common compound, the synthetic route is as follows.

General procedure: To a solution of [{M(mu-Cl)(ptpy)2}2] (M=Rh, Ir) (0.15mmol) in 25mL of a mixture of CH2Cl2/MeOH/H2O (1:1:0.5) the bipyridine ligand (0.3mmol) was added and the mixture refluxed with stirring for 3h. After cooling to room temperature KPF6 (0.5mmol) was added and stirred for 20min. The solvent was removed to dryness in vacuo and the residue dissolved in dichloromethane and chromatographed on alumina with CH2Cl2/acetone (9:1) as the eluent. The resulting solution was evaporated to dryness and the residue was redissolved in 5ml of dichloromethane and the product was precipitated by slow diffusion of isohexane.

4411-80-7, The synthetic route of 4411-80-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Graf, Marion; Gothe, Yvonne; Siegmund, Daniel; Metzler-Nolte, Nils; Suenkel, Karlheinz; Inorganica Chimica Acta; vol. 471; (2018); p. 265 – 271;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.99970-84-0,[2,2′-Bipyridine]-4,4′-dicarbaldehyde,as a common compound, the synthetic route is as follows.

99970-84-0, A mixture of 4,4′-diformyl-2,2′-bipyridine (234 mg,1.10 mmol) and 5-amino-1,10-phenanthroline (669 mg,3.43 mmol) in ethanol (50 mL) was heated to 80 C for12 h, giving a suspension. The reaction mixture was filtered hot, and the solid was washed with hot ethanol, affording the desired product as a yellow solid. Yield:486 mg (78 %). ESI-MS: m/z = 567.4 (M + H)+. 1HNMR (400 MHz, CDCl3): d = 7.68 (dd, J = 8.0, 4.8 Hz,2H), 7.74 (dd, J = 8.0, 4.4 Hz, 2H), 8.07 (dd, J = 5.2,1.2 Hz, 2H), 8.29 (dd, J = 2.8, 1.6 Hz, 2H), 8.31 (dd,J = 3.2, 1.6 Hz, 2H), 8.83 (dd, J = 8.4, 1.6 Hz, 2H), 8.88(s, 2H), 8.98 (d, J = 4.8 Hz, 2H), 9.07 (s, 2H), 9.19 (dd,J = 4.4, 2.0 Hz, 2H), 9.28 (dd, J = 4.4, 2.0 Hz, 2H). IR numax (KBr, cm-1): 3417 (br), 1628m, 1597s, 1554m,1505w, 1424m, 1383s, 1297w, 1206w, 1143w, 1062m,987w, 805w, 741s, 708w, 623w, 541w. Found: C 76.0, H3.8, N 19.7; Calcd for C36H22N8: C 76.3, H 3.9, N 19.8 %.

The synthetic route of 99970-84-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Cheng, Feixiang; Yu, Shiwen; Ren, Mingli; He, Chixian; Yin, Hongju; Transition Metal Chemistry; vol. 41; 3; (2016); p. 305 – 314;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

137848-29-4, (S)-2′-Amino-[1,1′-binaphthalen]-2-ol is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A mixture of 0.100 g (0.351 mmol) of (S)-NOBIN and 0.115 g (0.422 mmol) of 2-benz[a]anthraldehyde-1-ol were refluxed in absolute ethanol (10 mL) under argon for 10 h producing a dark redsolution and precipitate. The mixture was hot-filtered and washed with hot ethanol to produce a dark red solid that was dried in vacuo. Yield of (S)-2: 0.591 g, 81% from (S)-NOBIN. Melting point = 209 C;[alpha]D (20 C) = +126 (c = 1.04, THF); 1HNMR (CDCl3, 400 MHz): d 4.91(s, 1H, OH); 7.31 (d, 1H, J = 3.4 Hz, CH); 7.37 (m, 4H, CH); 7.41 (d, 1H,J = 3.8 Hz, CH); 7.43 (d, 1H, J = 1.8 Hz, CH); 7.61 (m, 4H, CH); 7.71 (d,1H, J = 2.8 Hz, CH); 8.05 (m, 4H, CH); 8.20 (d, 1H, J = 3.4 Hz, CH); 8.31(s, 1H, CH); 8.34 (d, 1H, J = 3.4 Hz, CH); 8.39 (d, 1H, J = 2.2 Hz, CH);8.41 (d, 1H, J = 2.2 Hz, CH); 8.92 (s, 1H, CH); 9.96 (s, 1H, CH); 14.98(s, 1H, OH). 13C NMR (CDCl3, 100 MHz): d 116.15, 116.25, 116.86,118.03, 119.74, 123.87, 124.84, 125.66, 125.82, 126.02, 126.48,126.74, 127.04, 127.14, 127.58, 128.00, 128.63, 128.76, 128.97,129.60, 129.78, 129.95, 130.61, 131.12, 131.24, 131.31, 131.33,132.85, 133.02, 133.80, 133.89, 137.33, 143.84, 151.39, 161.18,164.04. TOF-MS (m/z): [M]+ Calcd for C39H25O2N1 540.184, found 540.115. Anal. Calc. for C39H25O2N1: C, 86.80; H, 4.67; N, 2.60. Found:C, 86.59; H, 4.51; N, 2.43%. Single crystals suitable for X-ray analysis were grown by slow diffusion of hexane into a methylene chloride solution of (S)-2., 137848-29-4

As the paragraph descriping shows that 137848-29-4 is playing an increasingly important role.

Reference£º
Article; Barman, Sanmitra; Desper, John; Levy, Christopher J.; Polyhedron; vol. 84; (2014); p. 168 – 176;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

62937-45-5, D-Prolinamide is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

62937-45-5, (R)-chloro[(1,2,3,4,5-eta)-pentamethyl-2,4-cyclopentadien-1-y 1](2-pyrrolidinecarboxamidato-kappaN1, kappaN2)iridium(III) (Cp*Ir(Cl-) (R-PA-H+)) To 40 ml of methylene chloride, 1.593 g of a pentamethylcyclopentadienyl iridium(III) chloride dimer ([Cp*IrCl2]2), 502 mg of (R)-prolinamide and 425 mg of triethylamine were successively added, and the mixture was continuously stirred at room temperature overnight. To the reaction mixture, 10 ml of a 20% aqueous sodium chloride solution was added, and the mixture was stirred for about 30 minutes and then left to stand. The resulting layers were separated. The aqueous layer was extracted with 10 ml of methylene chloride, and then the organic layers were combined and washed with 10 ml of a 20% aqueous sodium chloride solution. Further, this aqueous layer was extracted with 10 ml of methylene chloride, and then the organic layers were combined and dried over 10 g of anhydrous sodium sulfate overnight. The desiccant was filtered off and washed with methylene chloride, and then the filtrate was concentrated in vacuo. To the concentrated residue, 20 ml of tetrahydrofuran/diisopropyl ether (1/1) was added, and the mixture was stirred at 35 to 40C for about 1 hour. The precipitate was collected by suction filtration, washed with 10 ml of tetrahydrofuran/diisopropyl ether (1/1), and then dried in vacuo at 40 to 50C for 5 hours to give 1.813 g of (R)-chloro[(1,2,3,4,5-eta)-pentamethyl-2,4-cyclopentadien-1-y 1](2-pyrrolidinecarboxamidato-kappaN1, kappaN2)iridium(III) (Cp*Ir(Cl-)(R-PA-H+)) as a yellow crystalline powder. Melting point: 174.8C Elemental analysis: C15H24ClIrN2O (476.01) calculated value (%) C37.84, H5.08, N5.88, Ir40.4 found value (%) C37.81, H5.07, N5.93, Ir40.7 IR (KBr): 3429, 3282, 1599 cm-1 1H-NMR (200 MHz, CDCl3) : delta 1.60-2.28 (4H, m, 2 * CH2), 1.70 (15H, s, 5Me of Cp*), 2.71-2.93 (1H, m, one of NCH2), 3.41-3.55 (1H, m, one of NCH2), 3.89-4.01 (1H, m, NCH), 4.96 (2H, br, 2 * NH). 13C-NMR (50.3 MHz, CDCl3) : delta 9.1 (5Me of Cp*), 27.1 (CH2), 28.2 (CH2), 54.3 (NCH2), 62.9 (NCH), 84.4 (ArC of Cp*), 183.5 (C=O).

As the paragraph descriping shows that 62937-45-5 is playing an increasingly important role.

Reference£º
Patent; Hamari Chemicals, Ltd.; MAEDA, Sadayuki; SATO, Tatsunori; KAWANO, Yasuhiko; MIYAWAKI, Toshio; EP2733138; (2014); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1662-01-7,4,7-Diphenyl-1,10-phenanthroline,as a common compound, the synthetic route is as follows.

(28A) tert-Butyl{3-[4-(3,4-dichlorobenzyloxy)phenyl]-3-vinyloxypropoxy}dimethylsilane3-(tert-Butyldimethylsilyloxy)-1-[4-(3,4-dichlorobenzyloxy)phenyl]propan-1-ol (300 mg, 0.680 mmol) produced in Example 27 (27B), palladium(II) trifluoroacetate (12 mg, 0.036 mmol), and 4,7-diphenyl-1,10-phenanthroline (12 mg, 0.036 mmol) were dissolved in butyl vinyl ether (5 mL), and triethylamine (20 muL, 0.14 mmol) was added thereto, and the resulting mixture was stirred under a nitrogen atmosphere at 80 C. for 4 hours. After cooling to room temperature, the reaction solution was filtered, and the solvent was distilled off under reduced pressure, whereby a crude product was obtained. This crude product was purified by silica gel column chromatography (hexane:ethyl acetate=100:0 to 96:4 (v/v)), whereby the objective title compound was obtained as a colorless oily substance (275 mg, yield: 87%).1H NMR (CDCl3, 400 MHz): delta0.04 (3H, s), 0.05 (3H, s), 0.91 (9H, s), 1.85 (1H, m), 2.07 (1H, m), 3.41 (1H, m), 3.57 (1H, m), 3.95 (1H, dd, J=1.6, 6.6 Hz), 4.23 (1H, dd, J=1.6, 14.1 Hz), 4.90 (1H, dd, J=5.1, 8.2 Hz), 5.00 (2H, s), 6.29 (1H, dd, J=6.6, 14.1 Hz), 6.92 (2H, d, J=9.0 Hz), 7.22 (2H, d, J=9.0 Hz), 7.24-7.28 (2H, m), 7.45 (1H, d, J=8.6 Hz), 7.54 (1H, d, J=2.0 Hz)

1662-01-7, 1662-01-7 4,7-Diphenyl-1,10-phenanthroline 72812, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; DAIICHI SANKYO COMPANY, LIMITED; US2011/53974; (2011); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI